###### Key messages

What is already known about this subject?
=========================================

-   The typical autoantibody of Sjögren\'s syndrome (SS), anti-SSA and anti-SSB antibody, is produced in salivary glands.

-   Anti-centromere antibody (ACA) is the major autoantibody detected in limited-cutaneous systemic sclerosis and primary biliary cirrhosis (PBC) but it is also detected in a part of SS patients' serum.

What does this study add?
=========================

-   In addition to anti-SSA/SSB antibody, ACA is also produced in the salivary glands of SS patients in an antigen-driven manner.

-   Serum ACA of patients with SS, SSc and PBC are commonly targeted to various sites of the centromere 'complex', not to individual proteins.

How might this impact on clinical practice or future developments?
==================================================================

-   This study highlights the significance of detail immunological analysis in local lesion for better understanding of disease-relevant autoantibody and classification of autoimmune diseases.

Introduction {#s1}
============

Serum autoantibody tests are widely used in clinical practice because the type of autoantibody is related to clinical course, treatment response and prognosis.[@R1] Sjögren's syndrome (SS) is an autoimmune disease that is characterised by chronic lymphocyte infiltration into salivary and lacrimal glands, that results in destruction of glands and causes sicca syndrome.[@R3] Anti-SSA antibody, which is collective term for multiple antibodies reacting to the SSA52 (TRIM21) and SSA60 (TROVE2), and anti-SSB antibody are the most commonly detected autoantibody in SS, and actually, anti-SSA antibody are used as one of the classification criteria of SS.[@R4]

Other autoantibodies, including anti-centromere antibody (ACA), anti-α-fodrin antibody and anti-muscarinic receptor three antibody, are also reported in a part of SS patients.[@R5] ACA is the major autoantibody detected in limited-cutaneous systemic sclerosis (lcSSc)[@R6] and primary biliary cirrhosis (PBC),[@R7] and clinically used in the classification criteria for systemic sclerosis (SSc),[@R8] but not included in the classification criteria for SS. In practice, ACA is detected by anti-nuclear antibody (ANA) test as discrete-speckled pattern (corresponding to the centromere region of chromosome). ELISA of anti-CENP-B antibody is also used because this result is highly consistent with ACA by ANA test.[@R9] In addition, CBX5, CENP-A, CENP-B and CENP-C are known to be the targets of ACA, although the reactivity against these proteins was reported to vary slightly depending on the disease; antibody against CBX5 and N-terminus of CENP-C are appear more frequently in SS than in SSc[@R10]; patients with primary SS have antibody that predominantly recognise CENP-C alone, whereas patients with SSc have antibody that recognise both CENP-B and CENP-C[@R11].

In addition to autoantibodies, there are similarities in clinical symptoms among ACA-positive diseases. ACA-positive SS has higher prevalence of Raynoud's phenomenon and sclerodactyly, which are the major symptoms of ACA-positive SSc, than SS without ACA.[@R12] However, the mutual relationship between these ACA-positive diseases has not been clarified.

Accumulating experimental evidence has identified the characteristics of anti-SSA/SSB antibody in SS as follows: IgA-type anti-SSA/SSB antibody are secreted into saliva[@R14]; anti-SSA/SSB antibody-secreting cells (ASCs) exist in salivary glands[@R15]; and B cells proliferate clonally in the salivary glands in an antigen-driven manner.[@R17] Recently, advanced single-cell technology has enabled the analysis of immunoglobulin heavy chain (IgH) and light chain (IgL) of each individual cell; therefore, we can reproduce antibody produced in vivo as recombinant proteins in vitro.[@R20] Several groups have reported that a high frequency of autoreactive/polyreactive antibody is observed in CD21^−/low^ and naïve B cells in peripheral blood of patients with SS,[@R21] whereas others reported increased frequencies of IgG-type ASCs in salivary glands that react to multiple autoantigens simultaneously.[@R24]

These studies have gradually revealed the nature of autoantibody produced in lesion site of SS. Therefore, we aim to clarify the overview of the autoantibody production at the lesion site including ACA-positive SS. Here, we isolated ASCs from salivary glands of patients with SS and comprehensively and efficiently reproduced their antibodies. We called these antibodies, produced by lymphocytes infiltrating in the disease lesion site, as 'lesion antibody', and by examining the reactivity of our lesion antibody panel, we revealed antigen-driven production of autoantibody against SSA, SSB and centromere 'complex' including a novel centromere-related autoantigen. Finally, we profiled the targets of ACA in patients with SS, SSc and PBC, and clarified the common reactivity of autoantibody among these patients.

Methods {#s2}
=======

Detailed methods are described in [online supplementary file 1](#SP1){ref-type="supplementary-material"}. We created 256 recombinant antibodies of ASCs in salivary glands from nine patients. The reactivity of these antibodies were investigated by ELISA and a newly developed procedure, antigen-binding beads assay. Antibodies against CBX5, CENP-A, CENP-B, CENP-C and MIS12 complex (MIS12C) were examined in 269 serum and 11 salivary gland tissues.
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Results {#s3}
=======

Identification of anti-SSA/SSB antibody in lesion antibody panel {#s3-1}
----------------------------------------------------------------

The IgH and IgL variable regions of ASCs derived from salivary glands were sequenced and used to produce lesion antibody panel. Patients' background and the number of antibodies are shown in [online supplementary table 3](#SP1){ref-type="supplementary-material"}. Of the 352 cells sorted, 256 recombinant antibodies were produced, the overall success rate was approximately 73%.

We first checked the polyreactivity of them since antibody derived from patients with autoimmune diseases are known to include polyreactive antibody.[@R25] The reactivity to lipopolysaccharide (LPS), insulin and dsDNA were examined, and antibody that reacted to two or more antigens were considered polyreactive. Among 256 antibodies, only three antibodies, LB20-34, LB20-80 and LB24-9, were polyreactive.

Next, we examined the reactivity of lesion antibodies using ELISA for anti-SSA52, anti-SSA60 and anti-SSB antibody. In addition, we examined the reactivity to antigens with native conformation by antigen-binding beads assay. Because SSA52 has Fc receptor activity,[@R26] all IgGs bound to SSA52-binding beads. Therefore, we used point mutated SSA52 (D355A), which lost Fc receptor activity,[@R27] to examine the reactivity against SSA52. Antibodies that exhibited reactivity by either ELISA or beads assay were regarded as positive. Antibodies binding to more than one antigen was counted as antibody for antigen with the highest titre. Since two polyreactive antibody, LB20-34 and LB20-80, bound to all three antigens but had the highest titre against SSB, they were counted as anti-SSB antibody.

Anti-SSA/SSB antibody profiles of serum and corresponding lesion antibodies are shown in [online supplementary table 4](#SP1){ref-type="supplementary-material"}. We identified seven anti-SSA52 antibodies, 23 anti-SSA60 antibodies and 15 anti-SSB antibodies in our panel. As previously reported,[@R15] autoantibodies were cloned only from the patients who were serum autoantibody positive. Between two detection procedures, antigen-binding beads assay had more sensitivity. There were six anti-SSA52, 15 anti-SSA60 and seven anti-SSB antibodies that were negative by ELISA but positive in beads assay. Among ASCs in salivary glands from serum anti-SSA/SSB antibody-positive patients, 30.6% of ASCs could produce anti-SSA/SSB antibody.

Antigen-driven selection of anti-SSA/SSB antibody {#s3-2}
-------------------------------------------------

Next, we focused on 12 anti-SSB antibodies found in one patient (LB20), and examined whether the epitopes of these antibody were identical. Since multiple epitopes of serum anti-SSB antibodies have been identified by western blotting,[@R5] we expressed three truncated forms of SSB protein, 1--107 amino acids (AA), 108--242 AA, and 243--408 AA, and examined which form the antibody reacted to. As shown in [figure 1A](#F1){ref-type="fig"}, epitopes differed depending on antibodies, suggesting that they were selected against whole SSB protein. Although LB20-34 and LB20-80 used in this experiment were polyreactive antibody, the epitope of SSB exists only in 1--108 AA region, indicating that the epitope recognised in one molecule could be specific, even among polyreactive antibody.

![Direct evidence of antigen-driven antibody selection against SSA and SSB. (A) GFP-fusion SSB fragments (Lane 1: 1--107 AA, Lane 2: 108--242 AA, and Lane 3: 243--408 AA) were isolated by SDS-PAGE. Anti-SSB antibody from one patient (LB20) was examined to determine which fragment they bound to. Anti-GFP antibody was used as a positive control. The band common to all anti-SSB antibodies at approximately 47 kDa was considered endogenous SSB. (B) Anti-SSA52, anti-SSA60 and anti-SSB antibody and their revertants were tested by ELISA at a concentration of 2 µg/mL. The vertical axis shows the OD at 450 nm. (C) Anti-SSA60 and anti-SSB antibody and their revertants were tested in antigen-binding beads assay. The reactivity of the antibody bound to SSA60-binding and SSB-binding beads was measured by flow cytometry. AA, amino acid; OD, optical density; SS, Sjögren\'s syndrome.](annrheumdis-2019-215862f01){#F1}

To directly examine whether the obtained autoantibody was selected in an antigen-driven manner, we created 17 revertant antibodies, which have all somatic hypermutations (SHMs) reverted to the genomic sequence, and examined the reactivity using ELISA and antigen-binding beads assay ([figure 1B--C](#F1){ref-type="fig"}). All of the revertant antibodies showed drastically decreased antigen reactivity by both ELISA and beads assay. Notably, two revertant antibodies created from anti-SSB antibody with polyreactivity lost polyreactivity after SHMs were reverted. Our results directly proved that most preselected autoantibody have no or poor binding ability, but they are selected and refined against autoantigens by accumulating SHMs.

Identification of a novel autoantigen in ACA-positive SS patient {#s3-3}
----------------------------------------------------------------

In our cohort, one patient (LB32) was serum ACA-positive by ANA test and serum anti-CENP-B antibody-positive by ELISA. We next examined whether ACA, like anti-SSA/SSB antibody, are also produced in salivary glands. First, we checked whether antibodies from LB32 react to CENP-B by ELISA, and surprisingly, none of the 39 antibodies reacted to CENP-B. For confirmation, we tested another manufacturer's ELISA, but the results did not change.

To investigate what these antibodies react to, we performed immunoprecipitation with a K562 cell lysate using these antibodies. Several proteins were precipitated by one of these antibodies, and identified by mass spectrometry ([figure 2A](#F2){ref-type="fig"}, [online supplementary file 2](#SP2){ref-type="supplementary-material"}). This result was verified by western blotting using antibody to DSN1, MIS12 and MIS12C ([figure 2B](#F2){ref-type="fig"}), and we further revealed that several antibodies derived from LB32 had similar reactivity.
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![Identification of the target of the lesion antibody derived from serum ACA-positive patients. (A) Immunoprecipitation was performed with cell lysate of K562 cells or lysis buffer using the LB32-8 antibody. The precipitated proteins were electrophoresed and stained by silver staining. The names of proteins identified by mass spectrometry are shown. The common bands at 50 kDa and 25 kDa are the heavy and light chains of the antibody, respectively. (B) The proteins that were immunoprecipitated from K562 cell lysate by each LB32 antibody were electrophoresed, and blotted with antibody against DSN1, Mis12 complex (MIS12C) and human IgG. (C) Three subcomplexes constituting the KMN assembly and their constituent proteins are shown. The identified proteins by mass spectrometry are shown in red. (D) The reactivity of antibody from LB32 was examined by antigen-binding beads assay. The indicated proteins were coupled with streptavidin beads. The reactivity against each autoantigen-binding beads was measured by flow cytometry. (E) An indirect fluorescent antibody test (ANA) of HEp-2 cells was performed using the anti-MIS12C antibody, LB32-9 and LB32-20, at a concentration of 50 µg/mL. Scale bar indicates 20 µm. ACA, anti-centromere antibody; ANA, anti-nuclear antibody.](annrheumdis-2019-215862f02){#F2}

These precipitated proteins were known to be constituents of KMN assembly in kinetochore complex.[@R29] KMN assembly consists of three subcomplexes, KNL1 complex (KNL1C), MIS12C and NDC80 complex (NDC80C), and the constituent proteins of these subcomplexes are shown in [figure 2C](#F2){ref-type="fig"}. We speculated that these antibodies precipitated whole KMN assembly; therefore, we next examined which protein the antibodies bound to. We expressed each protein in 293T cells, and used them for antigen-binding beads assay. As shown in [figure 2D](#F2){ref-type="fig"}, antibodies derived from LB32 did not bind to ZWINT1, a constituent of KNL1C, or to NUF2, SPC24 or SPC25, constituents of NDC80C, whereas they weakly bound to DSN1, NSL1, MIS12 and PMF1, constituents of MIS12C. Because it is unlikely that one monoclonal antibody (mAb) binds to four individual proteins, we speculated that when one of MIS12C constituent proteins was expressed, it would form complex together with other endogenous constituents, and antibody recognised the conformation of MIS12C. To verify this, we cotransfected all four constituent proteins of MIS12C and found that the reactivity was remarkably increased ([figure 2D](#F2){ref-type="fig"}), suggesting that these antibodies react to the complex form of MIS12C.

We further examined anti-MIS12C antibodies by ANA test. As expected, anti-MIS12C antibody showed discrete-speckled patterns ([figure 2E](#F2){ref-type="fig"}). Our results revealed that anti-MIS12C antibody is a novel member of ACA.

Identification of autoantibodies against various centromere-related proteins {#s3-4}
----------------------------------------------------------------------------

Next, we examined the reactivity of all of our lesion antibodies against MIS12C. In addition, other known targets of ACA, including CBX5, CENP-A, CENP-B and CENP-C, all of which are known to bind to MIS12C,[@R29] were also examined.

As shown in [online supplementary table 5](#SP1){ref-type="supplementary-material"}, antibodies derived from LB32 contained many anti-MIS12C and anti-CENP-C antibodies, and interestingly, antibodies derived from LB02, a serum ACA-negative patient, contained multiple types of ACA. Considering the time course between autoantibody production in lesion and its detection in serum, we checked the serum of LB02 2 years after salivary gland biopsy; however, it was still ACA negative. This finding indicates that the serum and salivary gland autoantibody profiles are not always consistent. In these two patients, approximately one-third of the cloned antibodies was ACA, and this proportion was comparable to that of anti-SSA/SSB antibody. Although one anti-CBX5 antibody was found among antibodies from LB01 (serum ACA negative, serum anti-CENP-B antibody negative), the possibility of a coincidence occurring could not be denied. A total of 24 ACA were found in our lesion antibodies by beads assay, but curiously, anti-CENP-B antibody could not be found in salivary glands, as previously shown by ELISA.

Antigen-driven selection of ACA {#s3-5}
-------------------------------

We next investigated whether ACA, like anti-SSA/SSB antibody, was selected in an antigen-driven manner. MIS12C is known to consist of two subcomplexes, MIS12-PMF1 and DSN1-NSL1[@R29]; therefore, we coexpressed MIS12 and PMF1 or DSN1 and NSL1 and examined which MIS12C-specific antibody reacted to.

As shown in [figure 3A](#F3){ref-type="fig"}, some of the anti-MIS12C antibodies recognised MIS12+PMF1, and others recognised DSN1+NSL1. Furthermore, there were antibodies that did not bind unless all four proteins were present. This result indicated that ACA recognised various sites of the target complex.

![Direct evidence of the antigen-driven antibody selection of ACA. (A) GFP, MIS12 and PMF1, DSN1 and NSL1, or the whole MIS12C was coupled with streptavidin beads. The reactivity of anti-MIS12C antibody against each beads was measured by flow cytometry. (B) Anti-MIS12C, anti-CENP-A and anti-CENP-C antibody and their revertants were tested by antigen-binding beads assay. The reactivity of antibody to each beads was measured by flow cytometry. ACA, anti-centromere antibody.](annrheumdis-2019-215862f03){#F3}

We also created revertant antibodies of ACA and examined their reactivity. As shown in [figure 3B](#F3){ref-type="fig"}, all of the revertant antibodies showed decreased antigen reactivity. These results directly proved that ACA were selected in an antigen-driven manner in salivary glands.

Serum ACA profile {#s3-6}
-----------------

Next, we examined whether the antibody specific for each centromere-related protein could also be detected in serum. We recruited a large cohort consisting of 112 patients who had sicca symptoms and suspected of having SS; 35 patients with SSc; 10 patients with PBC; 44 patients who had two or more complications of SS, SSc and PBC; and 68 healthy controls ([table 1](#T1){ref-type="table"}), and the presence of antibody specific for CBX5, CENP-A, CENP-B, CENP-C and MIS12C was examined.

###### 

Clinical characteristics of the patients performed serum analysis

  -----------------------------------------------------------------------------------------------------------
  Disease group                         HC            SS            SSc           PBC           Overlap
  ------------------------------------- ------------- ------------- ------------- ------------- -------------
                                        n=68          n=112         n=35          n=10          n=44

  Female %, (n)                         82 (56)       95 (106)      86 (30)       100 (10)      100 (44)

  Age median (IQR)                      44 (31--50)   59 (47--72)   59 (50--71)   60 (57--72)   64 (54--74)

  ACA positive % (n)                    NA            13 (14)       34 (12)       30 (3)        70 (31)

  Anti-CENP-B antibody positive % (n)   1.5 (1)       13 (14)       37 (13)       30 (3)        73 (32)

  Disease type/complicated disease, n                 pSS 71\       dcSSc 10\                   SS 32\
                                                      sSS 15\       lcSSc 25                    SSc 37\
                                                      non-SS 26                                 PBC 30
  -----------------------------------------------------------------------------------------------------------

dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc; NA, not accessed; PBC, primary biliary cirrhosis; pSS, primary Sjögren\'s syndrome; SS, Sjögren\'s syndrome; sSS, secondary Sjögren\'s syndrome.

As shown in [figure 4A](#F4){ref-type="fig"}, an IgG-type anti-MIS12C antibody as well as previously reported anti-CBX5, anti-CENP-A, anti-CENP-B and anti-CENP-C antibody[@R10] could be detected in serum, and the frequency of these antibody was highest in the overlap group. Because the IgA-type autoantibody was mainly produced in salivary glands,[@R14] and because all cloned ACAs were IgA, we also profiled the prevalence of IgA-type autoantibody ([figure 4B](#F4){ref-type="fig"}). Although IgA-type ACA was also detected in serum, the positivity was less clear than IgG-type ACA. Interestingly, the IgG/IgA ratio for each antigen varied, and the highest IgG/IgA ratio was observed for anti-CENP-B antibody ([figure 4C](#F4){ref-type="fig"}).

![Serum profile of antibody against centromere-related proteins. Serum samples from HC (n=68), patients suspected of having SS (n=112), patients with SSC (n=35), PBC (n=10) and OL diseases (n=44) were analysed by antigen-binding beads assay. (A) serum IgG bound to autoantigen-binding beads was assessed by flow cytometry. The dotted line indicates a cut-off, which was determined by receiver operating characteristic (ROC) analysis. The prevalence of each antibody is presented under the group label. (B) Serum IgA bound to autoantigen-binding beads was assessed by flow cytometry. (C) The ratio of IgG/IgA in ACA-positive serum is shown. Wilcoxon's test. (D). The correlation between the serum IgG reactivity to each centromere-related antigen is shown. The lower left panels are two-dimensional plots of the MFI of antigen-binding beads assay, and the numbers in the upper right panels indicate the correlation coefficient calculated by Spearman's test. (E) The number of antibody that each patient had was counted. The patients whose serum showed a discrete-speckled pattern in an ANA test are shown in black bars, and the other patients are shown in white bars. (F) Patients were classified according to the number of diseases of SS, SSC and PBC, and counted how many ACA each patient had. χ^2^ test. The number of patients in each group are shown at the centre of each pie chart. (G) The overlap of serum ACA (discrete-speckled pattern by the ANA test), anti-CENP-B antibody detected by ELISA, and anti-MIS12C antibody detected by the beads assay is shown in a Venn diagram. \*p\<0.0001. ACA, anti-centromere antibody; ANA, anti-nuclear antibody; HCs, healthy controls; MFI, mean fluorescence intensity; OL, overlapping; PBC, primary biliary cirrhosis; SS, Sjögren\'s syndrome.](annrheumdis-2019-215862f04){#F4}

To investigate the relationships among these antibodies, we examined the correlations among the titres of these antibodies in each individual ([figure 4D](#F4){ref-type="fig"}), and counted how many kinds of antibodies each patient had ([figure 4E](#F4){ref-type="fig"}). We found that these antibodies were moderately to highly correlated with each other, and most of serum ACA-positive patients had antibodies to four or five antigens. This result indicated that serum ACA-positive patients have antibodies to various portions of the centromere 'complex' rather than antibodies to specific centromere proteins. The highest prevalence of ACA was observed in the overlap group ([figure 4A](#F4){ref-type="fig"}). We further examined the relationship between the number of complicated diseases and the numbers of ACA, and found that the more these diseases the patients had, the more kinds of ACA became positive ([figure 4F](#F4){ref-type="fig"}).

Next, we investigated the dissociation among ACA by ANA test, anti-CENP-B antibody by ELISA, and anti-MIS12C antibody by beads assay. As shown in [figure 4G](#F4){ref-type="fig"}, many patients were commonly positive in all three assays; however, 21 patients were only anti-MIS12C antibody-positive. Although they may also include false positives, 6 of the 21 patients were also anti-CBX5 antibody-positive and 2 of the 21 patients were also anti-CENP-C antibody-positive, suggesting that in some patients, autoantibody could be detected only by the anti-MIS12C antibody test.

Direct detection of ACA-secreting cells in salivary glands {#s3-7}
----------------------------------------------------------

Finally, we directly confirmed the production of ACA in salivary glands. We expressed MIS12C, CBX5, CENP-A, CENP-B and CENP-C as GFP-fusion protein. Fresh-frozen sections of salivary glands were double stained with GFP-autoantigen and an antibody against CD138, the marker of ASCs.

The results are shown in [table 2](#T2){ref-type="table"}, and representative images are shown in [online supplementary figure 2](#SP1){ref-type="supplementary-material"}. ACA-secreting cells were detected in salivary glands of ACA-positive patients. We previously showed the patient who did not have serum ACA but did have ACA-secreting cells in salivary glands; however, patients like that one may not be frequent.

###### 

Clinical characteristics and results of the patients performed immunohistochemistry

  Patient ID                     S3              S10      Lip32     Lip73      Lip90    S20      Lip24    Lip28    Lip45    Lip47    Lip48
  ------------------------------ --------------- -------- --------- ---------- -------- -------- -------- -------- -------- -------- --------
  Sex                            Female          Female   Female    Female     Female   Female   Female   Female   Female   Female   Female
  Age                            51              71       31        29         70       58       36       76       58       38       47
  Disease                        sSS, MCTD       pSS      pSS       sSS, SSc   pSS      pSS      pSS      pSS      non-SS   non-SS   non-SS
  ANA titre                      \>1:2560        1:640    1:640     1:2560     1:320    1:1280   1:640    \<1:40   \<1:40   1:40     1:80
  ANA type                       s, c            h, d     h, d, n   d          h, c     s        s                          h, s     h, s
  Serum anti-SSA52/60 antibody   \+              \+       --        --         --       \+       \+       --       --       --       --
  Serum anti-SSB antibody        \+              --       --        --         --       \+       \+       --       --       --       --
  Serum anti-CENP-B antibody     \+              \+       \+        \+         \+       --       --       --       --       --       --
  Serum rheumatoid factor        \+              \+       --        \+         NA       \+       \+       --       NA       --       --
  Greenspan grade                3               3        4         4          4        3        4        3        2        2        1
  Medication                     PSL 10 mg/day   None     None      None       None     None     None     None     None     None     None
  Tissue ASCs                                                                                                                        
  Anti-GFP antibody\*            --              --       --        --         --       --       --       --       --       --       --
  Anti-MIS12C antibody\*         +++             +++      +++       +++        +++      --       --       --       --       --       --
  Anti-CBX5 antibody\*           --              --       ±         ±          --       --       --       --       --       --       --
  Anti-CENP-A antibody\*         ±               ±        \+        ++         ±        --       ±        ±        --       --       --
  Anti-CENP-B antibody\*         ±               ±        ±         \+         --       --       --       --       --       --       --
  Anti-CENP-C antibody\*         +++             +++      ++        +++        ++       --       --       --       --       --       --

\*Slides were examined at a magnification of ×200. -, undetectable; ±, one cell in multiple fields, +, 1--3 cells in one field; ++, 4--8 cells in one field; +++, \>8 cells in one field.

c, cytosol; d, discrete-speckled; h, homogeneous; MCTD, mixed connective tissue disease; n, nucleolar; NA, not assessed; PSL, prednisolone; pSS, primary Sjögren\'s syndrome; s, speckled; SS, Sjögren\'s syndrome; sSS, secondary Sjögren\'s syndrome.

Among ACA-related antigens, anti-MIS12C ASCs were detected most frequently, followed by anti-CENP-C ASCs. There were few antibody to other antigens, especially CBX5 and CENP-B. Interestingly, this frequency was somewhat consistent with the frequency of cloned ACA (11 anti-MIS12C antibodies, 10 anti-CENP-C antibodies, 2 anti-CBX antibodies, 1 anti-CENP-A antibody, and no anti-CENP-B antibody among 24 ACAs). As shown in [supplementary figure S2](#SP1){ref-type="supplementary-material"}, anti-MIS12C antibody, anti-CENP-A antibody, and anti-CENP-C antibody were detected in a same area of serial sections, indicating that these antibodies were produced in a centromere 'complex'-driven manner.

Discussion {#s4}
==========

In this study, we efficiently and comprehensively cloned antibodies from human salivary glands and investigated their reactivity. We succeeded in discovering direct evidence that ACA in addition to anti-SSA/SSB antibody are produced in lesions of SS in an antigen-driven manner. Moreover, we discovered a new autoantigen, MIS12C, in this process. Finally, we profiled the prevalence of ACA against several corresponding antigens in patients with SS, SSc, and PBC, and found that ACA-positive patients have antibodies against various sites of centromere 'complex' regardless of disease.

One of the advantages of our study is that incorporating recent single-cell techniques[@R32] enabled the efficient cloning of immunoglobulin sequences, resulting in successful cloning with 73% of sorted cells. Because ASCs were sorted without selection by their isotype, we could reproduce humoral immune responses in salivary glands in vitro without bias. This was confirmed by similarity between the antigen profiles of cloned ACA and ASCs in salivary gland tissues.

Another advantage of our study is the development of antigen-binding beads assay, which enable to detect autoantibodies recognising conformational epitopes. We found many anti-SSA52 and SSB antibodies that were negative by ELISA but positive by beads assay, but not vice versa. The novel target of ACA, MIS12C, was also found using this assay. These results suggest that most of autoantibodies target against conformational molecules, and a part of these antibodies recognise the linear parts of conformational molecules, which can detect by ELISA. This hypothesis enables to explain the discrepancy between previous studies and our results. In our study, most patients had several kinds of ACAs simultaneously, whereas the corresponding antigens of ACA were reported to differ depending on the disease[@R10]; our beads assay used recombinant protein produced in mammalian cell line, whereas previous studies used fragmented protein expressed by *E* *scherichia* *coli* or protein generated by in vitro transcription/translation.

We showed that ACA-positive patients have antibodies against various sites of centromere complex regardless of disease. The relationship between ACA and corresponding diseases is similar to the concept of anti-ARS antibody syndrome, in which anti-ARS antibody-positive patients often develop one or more diseases involving myositis, interstitial pneumonia and skin symptoms,[@R33] or mixed connective tissue disease (MCTD),[@R35] in which anti-U1RNP antibody-positive patients often develop one or more phenotypes resembling systemic lupus erythematosus (SLE), SSc, and myositis. Therefore, these ACA-positive patients may be classified as 'ACA-related disease' in addition to classical disease category. Additional study is desired for classification of these diseases.

We identified three polyreactive antibodies; two of them recognised disease-specific autoantigens such as SSB, while they bound to a specific part of the antigen, and reactivity decreased after SHM reversion. These results indicated that polyreactivity may accidentally emerge at least in part as a result of selection against a specific antigen.

One group reported that approximately one-third of peripheral naïve B cells from patients with SS recognises SSA52,[@R22] whereas we cloned only seven anti-SSA52 antibodies. In our antibody panel, some antibodies could bind to SSA60 and/or SSB and SSA52 simultaneously, suggesting the possibility that SSA52-specific antibody actually occurs less frequently, and most of so far 'anti-SSA52 antibody' are rather non-specific.

Anti-MIS12C antibody and anti-CENP-C antibody were mainly found among the cloned antibodies and by tissue staining, whereas few anti-CENP-B antibodies were found. The isotype of all of the cloned ACA were IgA, and serum IgG/IgA ratio of anti-MIS12C and anti-CENP-C antibody were also low. In contrast, serum IgG/IgA ratio of anti-CENP-B antibody was much higher. This finding indicated the possibility that antibody-producing mechanisms may differ depending on the corresponding antigens. For example, anti-MIS12C antibody and anti-CENP-C antibody were produced against centromere complex in salivary glands, whereas anti-CENP-B antibody was rarely produced in salivary glands for some reasons (eg, antigen is not exposed on the surface of complex, or antigenicity is low in the conformation of complex), but they are produced in other places, such as lymph nodes, after undergoing antigen processing.

In this study, we directly showed answers for some of the scientific questions about autoantibody, that anti-SSA/SSB antibody and ACA were produced in local lesions of SS in an antigen-driven manner, and that autoantibody can be produced against not only individual proteins but also protein complexes. Our strategy, separating various antibody included in serum into monoclonal populations, is somewhat similar to the relationship between bulk and single-cell RNA sequencing, and could produce the information with higher resolution. Because anti-citrullinated protein antibody-secreting cells have been detected in synovium of patients with rheumatoid arthritis,[@R36] it seems common that disease-specific antibody are produced locally in lesions. However, there are many remaining questions about autoantibody, such as why SSA/SSB and the centromere 'complex' can be targets in salivary glands, and whether these antibodies are involved in the destruction of salivary glands. In addition, new hypotheses were created from this study, including the relationship between autoantibodies and disease classification, and the difference in reactivity between serum and local antibodies. Further studies are needed to resolve these questions.
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